Luteolin Attenuates Diabetic Myocardial Hypertrophy by Inhibiting Proteasome Activity

Conclusion: This study indicates that luteolin protected against DCM in mice, including T1DM and T2DM, by upregulating phosphorylated protein AMPK and AKT/GSK-3 pathways while decreasing the proteasome activity. These findings suggest that luteolin may be a potential therapeutic agent for DCM.Pharmacology
Source: Pharmacology - Category: Drugs & Pharmacology Source Type: research